It takes money to make money. Most investors know that, but with business media so focused on the "how much," very few investors bother to ask, "How fast?"
When judging a company's prospects, how quickly it turns cash outflows into cash inflows can be just as important as how much profit it's booking in the accounting fantasy world we call "earnings." This is one of the first metrics I check when I'm hunting for the market's best stocks. Today, we'll see how it applies to Quanex Building Products (NYSE: NX ) .
Let's break this down
In this series, we measure how swiftly a company turns cash into goods or services and back into cash. We'll use a quick, relatively foolproof tool known as the cash conversion cycle, or CCC for short.
Why does the CCC matter? The less time it takes a firm to convert outgoing cash into incoming cash, the more powerful and flexible its profit engine is. The less money tied up in inventory and accounts receivable, the more available to grow the company, pay investors, or both.
5 Best Healthcare Equipment Stocks To Buy Right Now: Alnylam Pharmaceuticals Inc.(ALNY)
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its core product programs under clinical or pre-clinical development include ALN-TTR, a Phase I clinical trial program for the treatment of transthyretin-mediated amyloidosis; ALN-APC, a Phase I clinical trial program for the treatment of hemophilia; ALN-PCS for the treatment of severe hypercholesterolemia; ALN-HPN, a pre-clinical development for the treatment of refractory anemia; and ALN-TMP, a pre-clinical development for the treatment of hemoglobinopathies, including beta-thalassemia and sickle cell anemia. The company?s partner-based programs comprise ALN-RSV01, a Phase II clinical trial program for the treatment of respiratory syncytial virus infection; ALN-VSP, a Phase I clinical trial completed program for the treatment of liver cancers; and ALN-HTT, a pre-clinical development for the treatment of Huntington?s disease. It has strategic alliances with Novartis Pharma AG; F. Hoffmann-La Roche Ltd; Takeda Pharmaceutical Company Limited; Isis Pharmaceuticals, Inc.; Medtronic Inc.; Kyowa Hakko Kirin Co., Ltd.; and Cubist Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Advisors' Opinion:- [By Dan Carroll]
Biotech's known for volatility, and one of this year's biggest booms suffered a hit on that end this week. Alnylam Pharmaceuticals (NASDAQ: ALNY ) , which has seen shares explode for gains of more than 142% year to date in 2013, lost more than 11% this past week to rank as one of biotech's biggest busts over the last five days.
Best Building Product Stocks To Buy For 2014: Winning Brands Corp (WNBD)
Winning Brands Corporation is a manufacturer of cleaning solutions. The Company offers products in three markets: Consumer, Industrial and Commercial. Its Consumer products include 1000+ Stain Remover; KIND Laundry Detergent; KIND Fabric Softener; KIND Laundry Stain Remover, and CLEAN1 All Purpose. Its Industrial products include TrackMoist Dust Suppressant, and ReGuard-4 Equipment Cleaning for Emergency Responders. Its Commercial products include Professional Wet Cleaning Solutions. The Company owns 100% interests in Niagara Mist Marketing Ltd.
The consumer products are offered for sale through stores in various sectors, such as hardware, paint, convenience, and grocery. The industrial products are targeted for sale through professional property maintenance personnel in the case of TrackMoist and distributors to fire-fighting organizations in the case of ReGuard-4. The commercial products are for use by businesses in their line of work to generate a finished product, with an emphasis on the dry-cleaning sector, such as on cruise ships to perform cleaning of Dry Clean Only garments in substitution of the solvent perchloroethylene (Perc).
Advisors' Opinion:- [By Peter Graham]
Small cap stocks Beamz Interactive Inc (OTCBB: BZIC), EHouse Global (OTCBB: EHOS) and Winning Brands Corporation (OTCMKTS: WNBD) were all heading in different directions at the end of last week with the first small cap surging 49.94% while the other two sank 31.28% and 25.32%, respectively, on Friday. Moreover, all three small cap stocks are already heading in different directions again this morning. So where should investors and traders place their bets? Here is a closer look at all three small cap stocks:
Best Building Product Stocks To Buy For 2014: Akorn Inc.(AKRX)
Akorn, Inc. engages in the manufacture and marketing of diagnostic and therapeutic ophthalmic pharmaceuticals products, niche hospital drugs, and injectable pharmaceuticals in the United States and internationally. It offers products in various specialty areas, including ophthalmology, antidotes, anti-infectives, pain management, anesthesia, and vaccines. The company?s Ophthalmic segment markets diagnostic products, including mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, angiography dyes, and others primarily for use in the office setting. This segment also offers therapeutic products, such as antibiotics, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines, and anti-edema medications to wholesalers, chain drug stores, and other national account customers; and non-pharmaceutical products, which include various artificial tear solutions, preservative-free lubricating ointments, and eyelid cleansers. In addit ion, the Ophthalmic segment provides a line of over-the-counter dry eye and other eye health products principally under the TheraTears brand name through a chain drug stores and big box retailers, as well as directly to optometrists, ophthalmologists, and other eye care practitioners and clinics. The company?s Hospital Drugs and Injectables segment provides a line of niche hospital drug and injectable pharmaceutical products comprising antidotes, anti-infectives, controlled substances for pain management and anesthesia, and other pharmaceutical products to hospitals through the wholesale distribution channel. Its Contract Services segment manufactures ophthalmic and injectable pharmaceutical products for third party pharmaceutical customers based on their specifications. The company serves physicians, optometrists, hospitals, wholesalers, group purchasing organizations, pharmacy chains, and other pharmaceutical companies. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.
Advisors' Opinion:- [By Sean Williams]
What: Shares of Akorn (NASDAQ: AKRX ) �-- a hybrid generic and branded drug developer -- shed as much as 15% of their value after the company reported disappointing first-quarter results.
- [By Jake L'Ecuyer]
Equities Trading DOWN
Shares of Akorn (NASDAQ: AKRX) were down 9.41 percent to $23.39 after the company reported Q4 results and issued a weak FY14 guidance. - [By Ben Levisohn]
Still, some stocks are bucking the trend. Goodyear Tire & Rubber (GT) has gained 1.4% to $18.90, the largest gainer in the S&P 500, after reaching a deal with a union. The real winners: Hi-Tech Pharmacal (HITK) has gained 22.3% to $43.05 after agreeing to be purchased by Akorn (AKRX), which has jumped 9.6% to $18.02.
Best Building Product Stocks To Buy For 2014: Eastman Chemical Company (EMN)
Eastman Chemical Company, a chemical company, engages in the manufacture and sale of chemicals, plastics, and fibers in the United States and internationally. The company operates in four segments: Coatings, Adhesives, Specialty Polymers, and Inks (CASPI); Fibers; Performance Chemicals and Intermediates (PCI); and Specialty Plastics. The CASPI segment manufactures resins, specialty polymers, and solvents that are used in the production of paints and coatings, inks, adhesives, and other formulated products. The Fibers segment offers Estron acetate tow and Estrobond triacetin plasticizers used in cigarette filters; Estron natural and Chromspun solution-dyed acetate yarns for use in apparel, home furnishings, and industrial fabrics; and cellulose acetate flake and acetyl raw materials for acetate fiber producers. The PCI segment offers intermediates; performance chemicals; and complex organic molecules, such as diketene derivatives, specialty ketones, and specialty anhydrides for medical, pharmaceutical, fiber, and food and beverage ingredients, which are used in specialty market applications. This segment?s products are used in various markets and end uses, including agriculture, transportation, beverages, nutrition, pharmaceuticals, coatings, medical devices, toys, adhesives, household products, polymers, textiles, and consumer and industrial products, as well as used for health and wellness uses. The Specialty Plastics segment primarily offers engineering and specialty polymers, specialty film and sheet products, and packaging film and fiber products. This segment?s products include specialty copolyesters and cellulosic plastics, which are used in specialty packaging, in-store fixtures and displays, consumer and durable goods, medical goods, personal care and consumer packaging, photographic film, optical film, fibers/nonwovens, tapes/labels, and LCD?s. The company was founded in 1920 and is headquartered in Kingsport, Tennessee.
Advisors' Opinion:- [By Victor Selva] e exception. The firm has made an emphasis on its acetate tow production, mainly used for cigarettes. The company stands out for using coal as its input, in contrast with other competitors using petroleum and gas, both more expensive for production. This mark up has allowed Eastman to transfer some of its increasing costs onto prices, �without compromising its sales revenue.
In addition to this, the acquisition of Solutia Inc. (former global leader in performance materials) completed on July 2, 2012, broadened Eastman�� specialty chemicals output by adding automotive and solar end products to its portfolio.
Although Eastman is a highly diversified company, it has proven to be severely affected by negative cycles of the economy. Even though this feature is not appealing whatsoever to investments, it certainly has caused it to become a cheap alternative. And, a quite promising one, since the economic recovery boosted its revenue, as a result of Eastman�� focus on cost-advantage production methods.
Other specialty chemical competitors, such as Ashland Incorporated (ASH) didn�� show such a promising comeback, and the drop in revenue during 2012 was anticipated by investor Jean-Marie Eveillard (Trades, Portfolio), who sold out his 3.9 million share position by the third quarter of that year.
Another industry giant, Huntsman Corporation (HUN) did show more promising results, and less volatile revenues during these last years. This, of course, has led to a high price to earnings ratio discouraging investors as we see later.
Geographically Diversified
On 2012, almost 50% of Eastman sales were generated in North America, while more than 25% were in Asia and 20% in Europe, Middle East and Africa. This diversification is to be taken into account since it guarantees long-term revenue, even if cigarette consumption decreases in some specific region (for instance, American sales declined �in recent years),
Best Building Product Stocks To Buy For 2014: Callaway Golf Co (ELY)
Callaway Golf Company, incorporated on May 7, 1999, together with its subsidiaries, designs, manufactures and sells golf clubs (drivers, fairway woods, hybrids, irons, wedges and putters) and golf balls, and also sells golf accessories (such as golf bags, golf gloves, headwear, towels, umbrellas and travel gear) under the Callaway Golf and Odyssey brand names. The Company sells pre-owned golf products through its Website, www.callawaygolfpreowned.com. In addition, it sells Callaway Golf and Odyssey products direct to consumers online through its Websites shop.callawaygolf.com and www.odysseygolf.com. The Company also licenses its trademarks and service marks in exchange for a royalty fee to third parties for use on golf related accessories, including apparel, footwear, eyewear, rangefinders and practice aids. Its products are sold in the United States and in approximately 100 countries around the world.
The Company designs, manufactures and sells golf clubs and golf balls, and designs and sells golf accessories. The Company�� products are designed for golfers of all skill levels, both amateur and professional. The Company�� principal products include Drivers, Fairway Woods and Hybrids; Irons; Putters; Golf Balls, and Accessories, Softgoods and Other. Drivers, Fairway Woods and Hybrids product category includes sales of the Company�� drivers, fairway woods and hybrid products, which are sold under the Callaway Golf brand. Irons include sales of the Company�� irons and wedges, which are sold under the Callaway Golf brand. Putters include sales of the Company�� putters, which are sold under the Odyssey brand. Golf Balls includes sales of the Company�� golf balls, which are sold under the Callaway Golf and Strata brands. Accessories, Softgoods and Other includes sales of golf bags, golf gloves, golf footwear, rangefinders, golf apparel, packaged club sets, headwear, towels, umbrellas, eyewear and other accessories, as well as sales of pre-owned products through www.callawaygolfpre! owned.com. Additionally, this product category includes royalties from licensing of the Company�� trademarks and service marks on products such as golf apparel, golf footwear, rangefinders and practice aids.
The Company competes with TaylorMade, Ping, Acushnet, Puma, SRI Sports Limited, Mizuno, Bridgestone, and Nike.
Advisors' Opinion:- [By Peter Graham]
The Q3 2014 earnings report for small cap golf stock Callaway Golf Co (NYSE: ELY), a potential peer of sporting goods or sporting equipment stocks like Toronto listed�Performance Sports Group Ltd (NYSE: PSG) and Johnson Outdoors Inc (NASDAQ: JOUT), is scheduled for after the market closes on Thursday (October 23rd). Aside from the Callaway Golf earnings report, it should be said that Performance Sports Group Ltd reported Q1 2015 on October 9th (revenues were up 28% to $197.1 million) while the estimated release date for the Q4 2014 Johnson Outdoors Inc earnings report is�October 31st. However, Callaway Golf is the last publicly traded�pure play golf equipment stock�giving investors direct exposure to the game���especially since Dicks Sporting Goods Inc (NYSE: DKS)�recently took a $20.4 million pretax golf restructuring charge and plans to focus more attention on other sports.
- [By Jayson Derrick]
Analysts at Raymond James upgraded Callaway Golf (NYSE: ELY) to Strong Buy from a previous Market Perform with a price target of $9.50. The analysts are confident in the company's turnaround prospects. Shares gained 7.16 percent, closing at $8.53.
- [By Jake L'Ecuyer]
Callaway Golf (NYSE: ELY) was down as well, dropping 9.70 percent to $7.54 after the Dick's Sporting goods earnings report unveiled a weakness in the golf market which traders applied to Callaway, using it as a catalyst to push the shares lower.
Best Building Product Stocks To Buy For 2014: NewLink Genetics Corp (NLNK)
NewLink Genetics Corporation (NewLink), incorporated on June 4, 1999, is a development-stage company. The Company is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio includes biologic and small-molecule immunotherapy product candidates focused to treat a range of oncology indications. Its product candidate, HyperAcute Pancreas cancer immunotherapy (HyperAcute Pancreas), is being studied in a Phase-III clinical trial in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment (SPA), with the United States Food and Drug Administration (FDA). It has three additional product candidates in clinical development, including its HyperAcute Lung cancer immunotherapy (HyperAcute Lung), which is being studied in a Phase-I/II clinical trial conducted at the National Cancer Institute (NCI), and its HyperAcute Melanoma cancer immunotherapy (HyperAcute Melanoma), which is being studied in an investigator-initiated Phase-II clinical trial.
The Company�� HyperAcute product candidates are based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. It is also conducting small-molecule based research and development to produce new drugs capable of breaking the immune system's tolerance to cancer through inhibition of the indoleamine-(2,3)-dioxygenase (IDO), pathway. It is engaged in the study of IDO pathway inhibitor product candidate, d-1-methyltryptophan (D-1MT), in collaboration with the NCI, in two Phase 1B/II clinical trials.
HyperAcute Cancer Immunotherapy Product Candidates
In May 2010, the Company initiated Phase-III clinical trial for HyperAcute Pancreas. Its second product candidate, HyperAcute Lung, is in a Phase I/II clinical trial that is enrolled with 54 patients for the treatment of refractory, recurrent or metastatic nonresectable non-small cell lung cancer (NSCLC). Its Hyper! Acute Melanoma product candidate is being studied in an investigator-initiated, fully enrolled 25 patient Phase-II clinical trial for the treatment of advanced melanoma.
HyperAcute Cancer Immunotherapy Technology
The Company�� HyperAcute immunotherapies operate by exploiting a natural barrier present in humans that protects against infection being transmitted from other mammals. This barrier is related to the enzyme, alpha (1,3) galactosyl transferase, which is expressed in the cells of lower mammals. The presence of this enzyme results in the expression of a non-human form of carbohydrate called alpha (1,3) galactosyl carbohydrates (a-Gal), on the surface of affected cells. Its HyperAcute immunotherapy product candidates are composed of irradiated, live, allogeneic human cancer cells modified to express the gene that makes a-Gal epitopes. This exposure to a-Gal stimulates the human immune system to attack and destroy the immunotherapy cells on, which a-Gal is present by activating complement.
IDO Pathway Inhibitor Product Candidate
The Company is developing D-1MT, a small-molecule, orally bioavailable product candidate designed to inhibit the IDO pathway. In preclinical models, IDO pathway inhibitors have shown anti-tumor effects in combination with radiotherapy, chemotherapy, targeted therapy or immunotherapy. Through its collaboration with the NCI, it is studying D-1MT in two Phase 1B/II safety and efficacy clinical trials in various chemotherapy and immunotherapy combinations. One clinical trial combines D-1MT with an Ad-p53 autologous dendritic cell vaccine for solid malignancies with p53 mutations, such as lung, breast and colon cancers. The other clinical trial involves the combined use of D-1MT and Taxotere for patients with advanced stage solid tumors, for which Taxotere is the standard-of-care treatment, such as metastatic breast, prostate, ovarian and lung cancers.
Advisors' Opinion:- [By Ben Levisohn]
Biotech companies that are most likely to benefit because they are “Ahead in clinical development and/or have established relationships with [the Biomedical Advanced Research and Development Authority, or] BARDA which may facilitate getting a contract” include GlaxoSmithKline (GSK), NewLink Genetics (NLNK), Johnson & Johnson (JNJ) and Chimerix (CMRX). Kantor includes Tekmira�(TKMR) and Sarepta (SRPT) among “companies with viable programs” that are “moving forward and likely to attract additional funding.”
- [By Ben Rooney]
NewLink Genetics (NLNK) is working with the World Health Organization and other agencies on an Ebola vaccine. Its shares have surged 57% in the past month.
- [By Jayson Derrick]
NewLink Genetics (NASDAQ: NLNK) announced that it will discontinue the phase 3 IMPRESS clinical trial of algenpantucel-L for patients with pancreatic cancer. The company intends to regroup and ��athering additional, more mature data in support of our mission to provide improved treatment options for patients with pancreatic cancer.��Shares fell 16.20 percent, closing at $31.60.
No comments:
Post a Comment